Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-8

Very happy with this report. All these negative comments attacking the Bod, things are progressing nicely and the real fun begins next year with trial results, that’s why we are all here, but unfortunately some people are impatient.

At the time, CEO and Managing Director of Incannex, Mr Joel Latham said, “The initial Phase 2 proof of concept clinical trial over IHL-42X demonstrated an average reduction in our primary end point, AHI of 50.7%, with 25% of subjects having a reduced AHI of >80%. Importantly, we also observed a reduction in average patient oxygen desaturation index of 59.7%, markedly improved sleep quality and a reduction in cardiovascular stress. These results were truly remarkable and now allows for this Phase 2/3 trial to be a genuine long-term safety and efficacy trial. If we again observe such remarkable drug efficacy, safely administered over the 52 weeks, Incannex is confident that our product will be marketable.”

Share price today will be irrelevant if we knock the trial results out of the park, this is why I’m here to invest. If it was that easy to make money we would be all rich already, patience is key. Trial results don’t work, well we lose our money.